“Big enough to make a difference, small enough to care”

When the time came to choose a new owner for Aspironix, founder Jiří Pavlíček was looking for a long-term partner who shared his values relating to customer focus, entrepreneurship and deep responsibility - and he found it in Asker.

Aspironix, which has operations in the Czech Republic, Poland and Slovakia, is characterised by its innovative approach and expertise in wound care, surgery, cardiology, oncology and digital health.

For founder Jiří Pavlíček, development and progress is about more than new products and technologies – it's about finding new, practical ways to improve patient outcomes and support healthcare professionals in their daily work.

“Innovation in MedTech is about solving real challenges for patients and healthcare professionals, making healthcare safer, more efficient and more accessible,” says Jiří. "That's what motivates us every day."

This innovative force is part of the company's DNA. “At Aspironix, we strive for more, we deliver more, and ultimately our mission is to help. It's not just words, it's visible in our daily work,” says Jiří.

Finding the right partner

When it came time to considering the future of Aspironix, Jiří was clear about what he was looking for.

“I was looking for an owner who shared our values: long-term thinking, customer focus, entrepreneurship, responsiveness and a broader sense of responsibility than just numbers,” he recalls. “We met many players, including venture capital and private equity investors, but their focus was more on building and then selling on companies. That was not right for us. We wanted sustainability, and we felt a responsibility to our employees and our customers.”

Asker stood out for its values and clear vision. “After a year and a half, I can say that they have really lived up to our expectations,” says Jiří.

Unlimited possibilities

Becoming part of Asker brought immediate benefits. “After our first leadership conference as part of Asker, the word on everyone's lips was opportunities,” Jiří recalls. “The breadth that Asker brings is fantastic, but equally important is the reinforcement of its values. There is no hard governance, but rather a profound influence on how we work and collaborate.”

Becoming part of Asker has given Aspironix the opportunity to accelerate its growth. “Early on, we started exchanging ideas and knowledge with teams across the Group and broadening our offering. During the year, we also organised a workshop for experts within the Group to collaborate on innovative solutions for remote patient monitoring. We have only begun to scratch the surface, and the possibilities are limitless,” says Jiří.

The future: Big enough to make a difference, small enough to care

As Aspironix looks to the future, Jiří's vision is clear: “My hope for the company is that we keep our perspective of being big enough to make a difference, but small enough to continue to care. I don't want us to become a depersonalised big company structure. Asker does this very well – encouraging companies to remain entrepreneurial and work closely with their markets, while capitalising on the strength of the group.”

He continues: “It's about finding the right balance – moving fast enough to drive innovation, but always going deep enough to preserve our humanity and humility. This is how we deliver Health in Progress.”